The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0851
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC ; day:23 ; month:1 ; year:2022 ; pages:1-18
Cancer immunology immunotherapy ; (23.1.2022), 1-18

Creator
Guti, Eliza
Regdon, Zsolt
Sturniolo, Isotta
Kiss, Alexandra
Kovács, Katalin
Demény, Máté
Szöőr, Árpád
Vereb, György
Szöllősi, János
Hegedűs, Csaba
Polgár, Zsuzsanna
Virág, László
Contributor
SpringerLink (Online service)

DOI
10.1007/s00262-022-03146-z
URN
urn:nbn:de:101:1-2022050511035468557663
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Guti, Eliza
  • Regdon, Zsolt
  • Sturniolo, Isotta
  • Kiss, Alexandra
  • Kovács, Katalin
  • Demény, Máté
  • Szöőr, Árpád
  • Vereb, György
  • Szöllősi, János
  • Hegedűs, Csaba
  • Polgár, Zsuzsanna
  • Virág, László
  • SpringerLink (Online service)

Other Objects (12)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Related objects